Loading…

Choosing the right cell line for breast cancer research

Breast cancer is a complex and heterogeneous disease. Gene expression profiling has contributed significantly to our understanding of this heterogeneity at a molecular level, refining taxonomy based on simple measures such as histological type, tumour grade, lymph node status and the presence of pre...

Full description

Saved in:
Bibliographic Details
Published in:Breast cancer research : BCR 2011-08, Vol.13 (4), p.215-215, Article 215
Main Authors: Holliday, Deborah L, Speirs, Valerie
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-b552t-7a1face3a16e690c2125096b3dd79535d904c1b0d7671db37ffdb16435a5c9223
cites cdi_FETCH-LOGICAL-b552t-7a1face3a16e690c2125096b3dd79535d904c1b0d7671db37ffdb16435a5c9223
container_end_page 215
container_issue 4
container_start_page 215
container_title Breast cancer research : BCR
container_volume 13
creator Holliday, Deborah L
Speirs, Valerie
description Breast cancer is a complex and heterogeneous disease. Gene expression profiling has contributed significantly to our understanding of this heterogeneity at a molecular level, refining taxonomy based on simple measures such as histological type, tumour grade, lymph node status and the presence of predictive markers like oestrogen receptor and human epidermal growth factor receptor 2 (HER2) to a more sophisticated classification comprising luminal A, luminal B, basal-like, HER2-positive and normal subgroups. In the laboratory, breast cancer is often modelled using established cell lines. In the present review we discuss some of the issues surrounding the use of breast cancer cell lines as experimental models, in light of these revised clinical classifications, and put forward suggestions for improving their use in translational breast cancer research.
doi_str_mv 10.1186/bcr2889
format article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3236329</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A478424648</galeid><sourcerecordid>A478424648</sourcerecordid><originalsourceid>FETCH-LOGICAL-b552t-7a1face3a16e690c2125096b3dd79535d904c1b0d7671db37ffdb16435a5c9223</originalsourceid><addsrcrecordid>eNp1kUtLAzEUhYMo1hf-Axlw4aqaxySTuBBK8QWCGwV3Icnc6URmJppMBf-9U1pLC0oWCfd-9-RwLkKnBF8SIsWVdZFKqXbQAckFH_Ocvu1uvEfoMKV3jEkhudxHI0qkzEVODlAxrUNIvptlfQ1Z9LO6zxw0Tdb4DrIqxMxGMGkoms5BzCIkMNHVx2ivMk2Ck9V9hF7vbl-mD-On5_vH6eRpbDmn_bgwpDIOmCEChMKOEsqxEpaVZaE446XCuSMWl4UoSGlZUVWlJSJn3HCnKGVH6Gap-zG3LZQOuj6aRn9E35r4rYPxervT-VrPwpdmlAlG1SBwvRSwPvwjsN1xodWrOIfhi9XvMXzOIfW69WkRj-kgzJNWWFGpBJYDeb4kZ6YB7bsqDGJuQetJXsicDnEvqMs_qOGU0HoXOqj8UN8aWBlwMaQUoVobJ1gvNr9h9WwzqDX3u2r2A1NUqYs</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>909289608</pqid></control><display><type>article</type><title>Choosing the right cell line for breast cancer research</title><source>PubMed Central</source><creator>Holliday, Deborah L ; Speirs, Valerie</creator><creatorcontrib>Holliday, Deborah L ; Speirs, Valerie</creatorcontrib><description>Breast cancer is a complex and heterogeneous disease. Gene expression profiling has contributed significantly to our understanding of this heterogeneity at a molecular level, refining taxonomy based on simple measures such as histological type, tumour grade, lymph node status and the presence of predictive markers like oestrogen receptor and human epidermal growth factor receptor 2 (HER2) to a more sophisticated classification comprising luminal A, luminal B, basal-like, HER2-positive and normal subgroups. In the laboratory, breast cancer is often modelled using established cell lines. In the present review we discuss some of the issues surrounding the use of breast cancer cell lines as experimental models, in light of these revised clinical classifications, and put forward suggestions for improving their use in translational breast cancer research.</description><identifier>ISSN: 1465-542X</identifier><identifier>ISSN: 1465-5411</identifier><identifier>EISSN: 1465-542X</identifier><identifier>DOI: 10.1186/bcr2889</identifier><identifier>PMID: 21884641</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Animals ; Breast cancer ; Breast Neoplasms - metabolism ; Breast Neoplasms - pathology ; Cancer research ; Cell Line, Tumor ; Epidermal growth factors ; Estrogen Receptor alpha - metabolism ; Estrogens ; Female ; Gene expression ; Humans ; Mice ; Neoplastic Stem Cells - pathology ; Receptor, ErbB-2 - metabolism ; Receptors, Progesterone - metabolism ; Research Design ; Review ; Xenograft Model Antitumor Assays</subject><ispartof>Breast cancer research : BCR, 2011-08, Vol.13 (4), p.215-215, Article 215</ispartof><rights>COPYRIGHT 2011 BioMed Central Ltd.</rights><rights>Copyright ©2011 BioMed Central Ltd 2011 BioMed Central Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b552t-7a1face3a16e690c2125096b3dd79535d904c1b0d7671db37ffdb16435a5c9223</citedby><cites>FETCH-LOGICAL-b552t-7a1face3a16e690c2125096b3dd79535d904c1b0d7671db37ffdb16435a5c9223</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3236329/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3236329/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21884641$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Holliday, Deborah L</creatorcontrib><creatorcontrib>Speirs, Valerie</creatorcontrib><title>Choosing the right cell line for breast cancer research</title><title>Breast cancer research : BCR</title><addtitle>Breast Cancer Res</addtitle><description>Breast cancer is a complex and heterogeneous disease. Gene expression profiling has contributed significantly to our understanding of this heterogeneity at a molecular level, refining taxonomy based on simple measures such as histological type, tumour grade, lymph node status and the presence of predictive markers like oestrogen receptor and human epidermal growth factor receptor 2 (HER2) to a more sophisticated classification comprising luminal A, luminal B, basal-like, HER2-positive and normal subgroups. In the laboratory, breast cancer is often modelled using established cell lines. In the present review we discuss some of the issues surrounding the use of breast cancer cell lines as experimental models, in light of these revised clinical classifications, and put forward suggestions for improving their use in translational breast cancer research.</description><subject>Animals</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - metabolism</subject><subject>Breast Neoplasms - pathology</subject><subject>Cancer research</subject><subject>Cell Line, Tumor</subject><subject>Epidermal growth factors</subject><subject>Estrogen Receptor alpha - metabolism</subject><subject>Estrogens</subject><subject>Female</subject><subject>Gene expression</subject><subject>Humans</subject><subject>Mice</subject><subject>Neoplastic Stem Cells - pathology</subject><subject>Receptor, ErbB-2 - metabolism</subject><subject>Receptors, Progesterone - metabolism</subject><subject>Research Design</subject><subject>Review</subject><subject>Xenograft Model Antitumor Assays</subject><issn>1465-542X</issn><issn>1465-5411</issn><issn>1465-542X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNp1kUtLAzEUhYMo1hf-Axlw4aqaxySTuBBK8QWCGwV3Icnc6URmJppMBf-9U1pLC0oWCfd-9-RwLkKnBF8SIsWVdZFKqXbQAckFH_Ocvu1uvEfoMKV3jEkhudxHI0qkzEVODlAxrUNIvptlfQ1Z9LO6zxw0Tdb4DrIqxMxGMGkoms5BzCIkMNHVx2ivMk2Ck9V9hF7vbl-mD-On5_vH6eRpbDmn_bgwpDIOmCEChMKOEsqxEpaVZaE446XCuSMWl4UoSGlZUVWlJSJn3HCnKGVH6Gap-zG3LZQOuj6aRn9E35r4rYPxervT-VrPwpdmlAlG1SBwvRSwPvwjsN1xodWrOIfhi9XvMXzOIfW69WkRj-kgzJNWWFGpBJYDeb4kZ6YB7bsqDGJuQetJXsicDnEvqMs_qOGU0HoXOqj8UN8aWBlwMaQUoVobJ1gvNr9h9WwzqDX3u2r2A1NUqYs</recordid><startdate>20110812</startdate><enddate>20110812</enddate><creator>Holliday, Deborah L</creator><creator>Speirs, Valerie</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20110812</creationdate><title>Choosing the right cell line for breast cancer research</title><author>Holliday, Deborah L ; Speirs, Valerie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b552t-7a1face3a16e690c2125096b3dd79535d904c1b0d7671db37ffdb16435a5c9223</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Animals</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - metabolism</topic><topic>Breast Neoplasms - pathology</topic><topic>Cancer research</topic><topic>Cell Line, Tumor</topic><topic>Epidermal growth factors</topic><topic>Estrogen Receptor alpha - metabolism</topic><topic>Estrogens</topic><topic>Female</topic><topic>Gene expression</topic><topic>Humans</topic><topic>Mice</topic><topic>Neoplastic Stem Cells - pathology</topic><topic>Receptor, ErbB-2 - metabolism</topic><topic>Receptors, Progesterone - metabolism</topic><topic>Research Design</topic><topic>Review</topic><topic>Xenograft Model Antitumor Assays</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Holliday, Deborah L</creatorcontrib><creatorcontrib>Speirs, Valerie</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Breast cancer research : BCR</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Holliday, Deborah L</au><au>Speirs, Valerie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Choosing the right cell line for breast cancer research</atitle><jtitle>Breast cancer research : BCR</jtitle><addtitle>Breast Cancer Res</addtitle><date>2011-08-12</date><risdate>2011</risdate><volume>13</volume><issue>4</issue><spage>215</spage><epage>215</epage><pages>215-215</pages><artnum>215</artnum><issn>1465-542X</issn><issn>1465-5411</issn><eissn>1465-542X</eissn><abstract>Breast cancer is a complex and heterogeneous disease. Gene expression profiling has contributed significantly to our understanding of this heterogeneity at a molecular level, refining taxonomy based on simple measures such as histological type, tumour grade, lymph node status and the presence of predictive markers like oestrogen receptor and human epidermal growth factor receptor 2 (HER2) to a more sophisticated classification comprising luminal A, luminal B, basal-like, HER2-positive and normal subgroups. In the laboratory, breast cancer is often modelled using established cell lines. In the present review we discuss some of the issues surrounding the use of breast cancer cell lines as experimental models, in light of these revised clinical classifications, and put forward suggestions for improving their use in translational breast cancer research.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>21884641</pmid><doi>10.1186/bcr2889</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1465-542X
ispartof Breast cancer research : BCR, 2011-08, Vol.13 (4), p.215-215, Article 215
issn 1465-542X
1465-5411
1465-542X
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3236329
source PubMed Central
subjects Animals
Breast cancer
Breast Neoplasms - metabolism
Breast Neoplasms - pathology
Cancer research
Cell Line, Tumor
Epidermal growth factors
Estrogen Receptor alpha - metabolism
Estrogens
Female
Gene expression
Humans
Mice
Neoplastic Stem Cells - pathology
Receptor, ErbB-2 - metabolism
Receptors, Progesterone - metabolism
Research Design
Review
Xenograft Model Antitumor Assays
title Choosing the right cell line for breast cancer research
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-23T16%3A09%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Choosing%20the%20right%20cell%20line%20for%20breast%20cancer%20research&rft.jtitle=Breast%20cancer%20research%20:%20BCR&rft.au=Holliday,%20Deborah%20L&rft.date=2011-08-12&rft.volume=13&rft.issue=4&rft.spage=215&rft.epage=215&rft.pages=215-215&rft.artnum=215&rft.issn=1465-542X&rft.eissn=1465-542X&rft_id=info:doi/10.1186/bcr2889&rft_dat=%3Cgale_pubme%3EA478424648%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b552t-7a1face3a16e690c2125096b3dd79535d904c1b0d7671db37ffdb16435a5c9223%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=909289608&rft_id=info:pmid/21884641&rft_galeid=A478424648&rfr_iscdi=true